PURPOSE: To define a prostate fossa clinical target volume (PF-CTV) for Radiation Therapy Oncology Group (RTOG) trials using postoperative radiotherapy for prostate cancer. METHODS AND MATERIALS: An RTOG-sponsored meeting was held to define an appropriate PF-CTV after radical prostatectomy. Data were presented describing radiographic failure patterns after surgery. Target volumes used in previous trials were reviewed. Using contours independently submitted by 13 radiation oncologists, a statistical imputation method derived a preliminary "consensus" PF-CTV. RESULTS: Starting from the model-derived CTV, consensus was reached for a CT image-based PF-CTV. The PF-CTV should extend superiorly from the level of the caudal vas deferens remnant to >8-12 mm inferior to vesicourethral anastomosis (VUA). Below the superior border of the pubic symphysis, the anterior border extends to the posterior aspect of the pubis and posteriorly to the rectum, where it may be concave at the level of the VUA. At this level, the lateral border extends to the levator ani. Above the pubic symphysis, the anterior border should encompass the posterior 1-2 cm of the bladder wall; posteriorly, it is bounded by the mesorectal fascia. At this level, the lateral border is the sacrorectogenitopubic fascia. Seminal vesicle remnants, if present, should be included in the CTV if there is pathologic evidence of their involvement. CONCLUSIONS: Consensus on postoperative PF-CTV for RT after prostatectomy was reached and is available as a CT image atlas on the RTOG website. This will allow uniformity in defining PF-CTV for clinical trials that include postprostatectomy RT. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: To define a prostate fossa clinical target volume (PF-CTV) for Radiation Therapy Oncology Group (RTOG) trials using postoperative radiotherapy for prostate cancer. METHODS AND MATERIALS: An RTOG-sponsored meeting was held to define an appropriate PF-CTV after radical prostatectomy. Data were presented describing radiographic failure patterns after surgery. Target volumes used in previous trials were reviewed. Using contours independently submitted by 13 radiation oncologists, a statistical imputation method derived a preliminary "consensus" PF-CTV. RESULTS: Starting from the model-derived CTV, consensus was reached for a CT image-based PF-CTV. The PF-CTV should extend superiorly from the level of the caudal vas deferens remnant to >8-12 mm inferior to vesicourethral anastomosis (VUA). Below the superior border of the pubic symphysis, the anterior border extends to the posterior aspect of the pubis and posteriorly to the rectum, where it may be concave at the level of the VUA. At this level, the lateral border extends to the levator ani. Above the pubic symphysis, the anterior border should encompass the posterior 1-2 cm of the bladder wall; posteriorly, it is bounded by the mesorectal fascia. At this level, the lateral border is the sacrorectogenitopubic fascia. Seminal vesicle remnants, if present, should be included in the CTV if there is pathologic evidence of their involvement. CONCLUSIONS: Consensus on postoperative PF-CTV for RT after prostatectomy was reached and is available as a CT image atlas on the RTOG website. This will allow uniformity in defining PF-CTV for clinical trials that include postprostatectomy RT. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Kirsty L Wiltshire; Kristy K Brock; Masoom A Haider; Daniel Zwahlen; Vickie Kong; Elisa Chan; Joanne Moseley; Andrew Bayley; Charles Catton; Peter W M Chung; Mary Gospodarowicz; Michael Milosevic; Andrew Kneebone; Padraig Warde; Cynthia Ménard Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-15 Impact factor: 7.038
Authors: Philip Poortmans; Alberto Bossi; Katia Vandeputte; Mathieu Bosset; Raymond Miralbell; Philippe Maingon; Dirk Boehmer; Tom Budiharto; Zvi Symon; Alfons C M van den Bergh; Christopher Scrase; Hendrik Van Poppel; Michel Bolla Journal: Radiother Oncol Date: 2007-08-13 Impact factor: 6.280
Authors: Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford Journal: JAMA Date: 2006-11-15 Impact factor: 56.272
Authors: Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh Journal: JAMA Date: 2008-06-18 Impact factor: 56.272
Authors: R K Valicenti; L G Gomella; M Ismail; S G Mulholland; R O Petersen; B W Corn Journal: Int J Radiat Oncol Biol Phys Date: 1998-10-01 Impact factor: 7.038
Authors: Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Alan Dal Pra; Cedric Panje; Thomas Zilli; Winfried Arnold; Kathrin Brouwer; Helena Garcia; Markus Glatzer; Silvia Gomez; Fernanda Herrera; Khanfir Kaouthar; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Rudolf Zwahlen; Daniel Engeler; Paul Martin Putora Journal: Strahlenther Onkol Date: 2017-06-27 Impact factor: 3.621
Authors: S Gwynne; E Spezi; D Sebag-Montefiore; S Mukherjee; E Miles; J Conibear; J Staffurth Journal: Br J Radiol Date: 2013-02-07 Impact factor: 3.039
Authors: Emma Holliday; Clifton D Fuller; Jayashree Kalpathy-Cramer; Daniel Gomez; Andreas Rimner; Ying Li; Suresh Senan; Lynn D Wilson; Jehee Choi; Ritsuko Komaki; Charles R Thomas Journal: J Radiat Oncol Date: 2015-11-03